Unfortunately, there is still no gold standard definition of high-level MET amplification and this also differs per technique used.31 There are signals that MET amplified NSCLC might be sensitive to immune checkpoint inhibitors, however only limited and retrospective research has been done.32,33 Therefore, compounds like OMO-1 combining potential immunomodulatory effects with targeted therapy could be an interesting mode of therapy for this group, although the actual immunomodulatory effects of OMO-1 in vivo remain unclear. Here, MET is linked to non-small cell lung carcinoma.